07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

BCI-838: Phase I data

A double-blind, placebo-controlled, Dutch Phase I trial in healthy volunteers showed that multiple ascending-doses of oral BCI-838 were well tolerated. There were no treatment-related trends in clinical laboratory results, vital sign measurements, 12-lead electrocardiogram results...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

Sorbent management update

Sorbent Therapeutics Inc. , Sunnyvale, Calif.   Business: Renal, Cardiovascular   Hired: Jason Levin as CBO, a newly created position, formerly CBO of BrainCells Inc.  ...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Clinical News

BCI-838: Phase I data

A double-blind, placebo-controlled, Dutch Phase I trial in 31 healthy volunteers showed that single ascending-doses of up to 900 mg oral BCI-838 were well tolerated with no severe adverse events reported. BrainCells expects to complete...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Depomed management update

Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif.   Business: Endocrine, Neurology, Drug delivery   Hired: James Schoeneck, a director, as president and CEO, formerly CEO of BrainCells Inc. ; he replaces Carl Pelzel, who resigned  ...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Company News

BrainCells, Proximagen deal

BrainCells will acquire exclusive, worldwide rights to develop and commercialize Proximagen's sabcomeline . The selective muscarinic acetylcholine receptor M1 ( CHRM1 ; HM1 ) partial agonist is in Phase II testing to treat schizophrenia. BrainCells...
07:00 , Apr 8, 2010 |  BC Innovations  |  Cover Story

Managing microglia in Alzheimer's

Microglia are often found near damaged tissue in Alzheimer's disease patients, but whether the brain's innate immune cells are helpful or harmful in the disease has been an open question. Now, German researchers have evidence...
07:00 , Apr 1, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3) An in vitro study suggests that antagonizing MGLUR2 and MGLUR3 could be useful...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

BCI-952: Phase II data

A modified intent-to-treat (mITT) analysis of 134 patients in a double-blind, U.S. Phase II trial showed that BCI-952 met the co-primary endpoint of significantly improving mean CGI-I score at week 6 compared with placebo (p=0.046),...
00:07 , Jul 28, 2009 |  BC Extra  |  Clinical News

BrainCells reports BCI-952 data

BrainCells Inc. (San Diego, Calif.) reported mixed results from a Phase II trial of BCI-952 to treat major depressive disorder (MDD). A modified intent-to-treat (ITT) analysis showed the combination of low-dose buspirone and melatonin met...